{"name":"N4 Pharma UK Ltd.","slug":"n4-pharma-uk-ltd","ticker":"","exchange":"","domain":"","description":"N4 Pharma UK Ltd. is a specialty pharmaceutical company focused on the development of novel formulations of established drugs. The company's pipeline includes two sildenafil-based products, one already marketed and another in Phase 3 clinical trials.","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Oral sildenafil","genericName":"Oral sildenafil","slug":"oral-sildenafil","indication":"Other","status":"marketed"},{"name":"Sublingual sildenafil","genericName":"Sublingual sildenafil","slug":"sublingual-sildenafil","indication":"Erectile dysfunction","status":"phase_3"}]}],"pipeline":[{"name":"Oral sildenafil","genericName":"Oral sildenafil","slug":"oral-sildenafil","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sublingual sildenafil","genericName":"Sublingual sildenafil","slug":"sublingual-sildenafil","phase":"phase_3","mechanism":"Sublingual sildenafil works by increasing blood flow to the penis to treat erectile dysfunction.","indications":["Erectile dysfunction"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNSmVvVkppTkNvekxLSHgzOGtFcGJnMGNySF9EbzFFdGtjVDRxcUQ2dU5NZTdVaWFLRk1oTFZFaDZpYlFNd0p5UERwZFJxRThMaFQxTjVPMUgzaU4wRFNqM0ZZOG5oOHR5UlVOeE1HUmVvNFdXVWFremdKaFhwUFZDY3pRdHBmZm9sWElFdFRHZnBMUGFBaUVjZmpjWQ?oc=5","date":"2026-04-02","type":"pipeline","source":"investments.halifax.co.uk","summary":"Market news - investments.halifax.co.uk","headline":"Market news","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1ONXA5OV9RclBEd2dRd2taMF9fTGtBZVZoX1BBc2QzaXNtOFAxQkNVREdMa3dQUXEwUGR4SkhZQUtMOVFycFprYjFXYzNOMWRMTVU1SE1iUWlPcGpFNzdnYUdtck0zWWJjVV9lMF9aellVOFFDQ1ZvZjRyNDF5QQ?oc=5","date":"2026-03-17","type":"pipeline","source":"Share Talk","summary":"N4 Pharma changes name to Thalia Therapeutics - Share Talk","headline":"N4 Pharma changes name to Thalia Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQY1dkMFhWcWVrdkNpaEFWRkQxRXBjNWtpOF9QLWw2UmJVeDh1dU9tNDBkUGM1S05vNElGcVM2dUdCbFBQLU9IZVNIel9FQzlocmFJbTcyZFpFYVNvS0hsU3BzamM2WkVLTzdrOHdQTkJMcFJBNWNqUmpnS0syOTJMWk9yUFBUZw?oc=5","date":"2026-03-02","type":"pipeline","source":"PMLiVE","summary":"N4 Pharma appoints David Solomon as CEO - PMLiVE","headline":"N4 Pharma appoints David Solomon as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSURIRUlqLXZPV2VhSmM4cjdJWVdRalBVTjRvRzNCdUZKbjdFVVMtcjVOOEhvQTdGQi1uNEdVZlBoSHpkODcxUWppTGZJaF9ZZ1pjaHJvWEdxNnVJNEZic0cySlVTa0tJRHVYS3EzckdhUVFHRGJKMngwcFpwVGR3Rk0zbUNrbWZjQmNoY3NtQkV0WnB2YkVlaUYtRlM1cmNLQS1valZpVlUxMEE?oc=5","date":"2026-02-27","type":"pipeline","source":"Investing.com","summary":"N4 Pharma plans name change to Thalia Therapeutics - Investing.com","headline":"N4 Pharma plans name change to Thalia Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNX3Z3aTFoczIzc0JNbnFsN18tNlpibDVNa2thd3dJN19NY2N5MWo5ei1tMjdrUDdkMjd6cEVIZWY2dVQwOU9HWmdPVE5TQ29FeTZPVzJoS05VMkNGR2JTVUpBMkd6WXhta3B3REpVX0pRVW1Ba3JqckVtM2xSdVZHN1MxRENHZi1FemFnRnJDa0NXektEMXNRZjl2eTEzeUpoM0xyVFAxQjVWYnpNODdhWDltMA?oc=5","date":"2026-02-24","type":"pipeline","source":"The Pharma Letter","summary":"N4 pivots to RNA with new chief exec and Thalia rebrand - The Pharma Letter","headline":"N4 pivots to RNA with new chief exec and Thalia rebrand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNNXJWYjc1WFJIcE11dTV2UHBrWjJZcl95ak16ODF1SU9Ob1lOb2NYeXhfdGlYQTAtSzA1NFFZbDFTcEUyNjJXU3lQOWlsOEdWZmtaRHpLYnJfWFQtZWYxbWp0a2picTJaNDg2TTl0Q0x2dEFvcDRLMVJFVzUzblRVQ0RYUEtHSW1YNnJrdGl1MWtoZC1TSXBfRk1KU1FyUQ?oc=5","date":"2026-02-24","type":"pipeline","source":"Share Talk","summary":"N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics - Share Talk","headline":"N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNaGJNRFdwN2c5aW8xNzJFOGNzRFZubi0xckJzQWFjcFh2aUxISDhyalZTaG80ejEyUkx4UUNfRVZXblJmTXItVFdMMzQ1ajVNNGkyV0M4QldPaTZZN19jM25fdTlTUlRrRHN5NGZ2TEZkUjVIZ0U5bGRXYXA4OEVaZExPYUV6UHpTaGNPUHprdEh6c2FuaGgwMjRWTDczQQ?oc=5","date":"2025-09-25","type":"pipeline","source":"TheBusinessDesk.com","summary":"City briefs: N4 Pharma; Journeo; Microlise - TheBusinessDesk.com","headline":"City briefs: N4 Pharma; Journeo; Microlise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNSHlDV2RyTXVnNTFyWk01SVJKdGxkSWRrQnZfTkFHb050cHZjdWF5d3JCZmRCd3NXRmFyWUNXa1Atc3BhZk5ZNmhfWlBGWEU1MkdTbUFTVmt4Q19KUnp5MXhBeVR1aDFaNGgydEZBS1JCRTgtVFZDMFJyeVlrR1RtQ0VFUVJZTFRlMC1mb1BXQV9NRVJfZnp6Yjllc25QUUJ4M3pXZkY2SnMwMEcxU0VEcGozTzlnS2s?oc=5","date":"2025-09-23","type":"deal","source":"Share Talk","summary":"N4 Pharma plc (AIM: N4P) Partnership with University of Strathclyde's CMAC National Facility - Share Talk","headline":"N4 Pharma plc (AIM: N4P) Partnership with University of Strathclyde's CMAC National Facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNZE1oUHVUZkczMFhpclpVVGJlM0l1Nkc4aFJjV0xmVjU1Q2hCZDZQNHBDUFF4LVc2bmYwMXdUSE1ETW5Fdkx1dm1OdVFxejRtN3ZrRTNxWXl0N3ZPdk9xTmJ4NnBRdVNZZjVQN2FLanBub0kwWlZMNUJKREZuMDAxelZ0VmNUWC1lMWlaQ0tkeVduTVp6UE5ZZ3JBQQ?oc=5","date":"2025-06-06","type":"pipeline","source":"investments.halifax.co.uk","summary":"Market news - investments.halifax.co.uk","headline":"Market news","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQTXhidG5JV1JFTDg3bkdyWFA3WmlYT29NcWhXRGNfXy1rT0tPcjVpMS1UVnd6U3FLU3ZNYW9CcVJJNVVvWnNSWW1GVTU1R0RUTkh0eWJncVk1T2I3cndhaFFsZ2R4QnAyNURZRFJrbm13LXdNLXZBa3g1dmxoVE1VazhGbU5rQURQN05QSWpoVzlNa0U3YVQ2RnptUUg1dXBGdzlJLWNYTHBUQTFRQ0ZXNA?oc=5","date":"2024-06-30","type":"pipeline","source":"SelectScience","summary":"N4 Pharma highlights potential of Nuvec as gene therapy delivery platform - SelectScience","headline":"N4 Pharma highlights potential of Nuvec as gene therapy delivery platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQMllFcTFENFRzQzB6Q05lNjVRT25YWXlWTnpKNFUzbVlyeWFWNl9Rb18xTlBwMnhxRFE1SGRZel9pbmV1UU1hdC1NWHdtMmFPQ19qVFpxSTZBbHpjZEl1dFR5ODlWYU9OVGdQYVhkVXZHYWlpQ09DWmlzdHUwXzFfR3RCdmphdjh0LTNVal9LdWg?oc=5","date":"2024-03-04","type":"pipeline","source":"Manufacturing Chemist","summary":"N4 Pharma’s Nuvec and LipTide delivery systems advance towards commercialisation - Manufacturing Chemist","headline":"N4 Pharma’s Nuvec and LipTide delivery systems advance towards commercialisation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPbXZtUzMxSzk4N2x6WjZuaDJ5TmhhMzdSeml4M3hBeGhxdDZab21oeWYwMGprNDdaWkM1SHk4dTFPdGZrRW41UFBvTTE3UEhsUV9hYXJVQkw5cHY4aDhod1pRQ3M1Z2JiWUY4TmNEQld1bkhHa3lROTZQbUFoWll1NldfeGdWbE1uQ1RGTUhUZzJSQm5LSlgxRUgxbndPXzFleHRsdFczOEFPSTZVTUJfOFVySW02Z1A0UGZEOWNxNGRPN041XzlaWnBueHJ4VFBsckI1Mmw4YnRjcUk?oc=5","date":"2024-01-16","type":"trial","source":"DirectorsTalk Interviews","summary":"N4 Pharma’s Nanogenics signs contract for pre-clinical study of ECP105 for Glaucoma treatment - DirectorsTalk Interviews","headline":"N4 Pharma’s Nanogenics signs contract for pre-clinical study of ECP105 for Glaucoma treatment","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}